Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

5.4K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
5.4K
Signs of Puberty01:27

Signs of Puberty

1.9K
Puberty is a critical phase, typically beginning between the ages of 8 and 13 in girls and 9 and 14 in boys, though timing can vary based on genetics, environmental factors, and overall health. This period is characterized by the development of secondary sexual characteristics and the attainment of reproductive potential. Endocrine changes underpin puberty, with hormonal surges of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) instigated by Gonadotropin-Releasing Hormone (GnRH)...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-Glucocorticoid Immunosuppressive Therapy in Post-Glucocorticoid Persistent or Recurrent Primary Autoimmune Hypophysitis: A Systematic Review.

Clinical endocrinology·2026
Same author

Diagnostic Performance of Parathyroid CT and CT-Guided Targeted Parathyroidectomy in MEN1-Associated Primary Hyperparathyroidism.

Annales d'endocrinologie·2026
Same author

Triple-tracer Functional Imaging in a Rare Case of Thyroid Paraganglioma.

Clinical nuclear medicine·2026
Same author

Ultrasound-Guided Percutaneous Ethanol Injection for the Treatment of Cystic and Predominantly Cystic Thyroid Nodules: A Single-Centre Experience.

Indian journal of endocrinology and metabolism·2026
Same author

Diagnostic and Management Challenges in Pheochromocytoma and Paraganglioma: A Clinical Review.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2026
Same author

3β-Hydroxysteroid dehydrogenase type-2 deficiency: Our experience and gonadal function-focused systematic review.

Endocrine·2026

Related Experiment Video

Updated: Mar 28, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

20.1K

Gender differences in macroprolactinomas: a single centre experience.

Shruti Khare1, Anurag R Lila2, Hiren Patt2

  • 1Department of EndocrinologySeth GS Medical College and KEM Hospital, Parel, Mumbai 400012, India shrutigkhare@yahoo.co.in.

Endocrine Connections
|December 20, 2015
PubMed
Summary

Macroprolactinomas affect both sexes equally, with males presenting larger tumors and mass effect symptoms, while females experience hypogonadism. Both genders show similar cabergoline responsiveness, challenging prior hypotheses on gender-specific tumor growth.

Keywords:
cabergoline resistancegender differencesmacroprolactinomaresponsiveness

More Related Videos

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

1.7K
Quantification of Levator Ani Hiatus Enlargement by Magnetic Resonance Imaging in Males and Females with Pelvic Organ Prolapse
07:41

Quantification of Levator Ani Hiatus Enlargement by Magnetic Resonance Imaging in Males and Females with Pelvic Organ Prolapse

Published on: April 17, 2019

10.5K

Related Experiment Videos

Last Updated: Mar 28, 2026

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas
07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

20.1K
Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

1.7K
Quantification of Levator Ani Hiatus Enlargement by Magnetic Resonance Imaging in Males and Females with Pelvic Organ Prolapse
07:41

Quantification of Levator Ani Hiatus Enlargement by Magnetic Resonance Imaging in Males and Females with Pelvic Organ Prolapse

Published on: April 17, 2019

10.5K

Area of Science:

  • Endocrinology
  • Oncology
  • Pituitary Disorders

Background:

  • Macroprolactinomas, the most common functional pituitary tumors, exhibit unexplained gender-based size differences.
  • Previous hypotheses suggested diagnostic delays in males and differing tumor proliferation rates contribute to this disparity.

Purpose of the Study:

  • To compare gender-specific clinical, biochemical, and radiological features of macroprolactinomas.
  • To evaluate differences in management outcomes and cabergoline responsiveness between males and females.
  • To investigate potential gender-based disparities in macroprolactinoma presentation and treatment.

Main Methods:

  • Analysis of baseline characteristics in 100 macroprolactinoma patients (56 females, 44 males).
  • Assessment of drug responsiveness in 88 treatment-naive patients using cabergoline (3.5 mg/week for ≥6 months).
  • Drug resistance defined as failure to normalize prolactin and achieve >50% tumor volume reduction.

Main Results:

  • Females presented at a younger mean age (30.29±10.39 years) than males (35.23±9.91 years).
  • Females predominantly reported hypogonadism (96.15%), while males exhibited mass effect symptoms (93.18%).
  • Males had significantly larger tumors (3.93±1.53 cm) and higher baseline prolactin levels (7927.07±16748.1 ng/ml) than females.
  • Tumor drug resistance rates were similar between sexes (27.77% females vs. 35.29% males), irrespective of tumor size.

Conclusions:

  • Macroprolactinomas are equally prevalent in both males and females.
  • Clinical presentation differs significantly, with males showing mass effect symptoms and females experiencing hypogonadism.
  • Males harbor larger tumors, yet cabergoline responsiveness is comparable between genders, indicating similar treatment efficacy.